Publications by authors named "A Ukimura"
Clostridioides difficile, a cause of healthcare-associated infections, poses a significant global health threat. This multi-institutional retrospective study focuses on epidemic dynamics, emphasizing minor and toxin-negative clinical isolates through high-resolution genotyping. The genotype of the C.
View Article and Find Full Text PDFBackground: Infective endocarditis (IE) caused by MRSA (methicillin-resistant Staphylococcus aureus) is associated with a high mortality rate. This study aimed to elucidate the characteristics of patients with MRSA-IE in Japan and identify the factors associated with prognosis.
Methods: This retrospective study included patients with a confirmed diagnosis of IE caused by MRSA, between January 2015 and April 2019.
Article Synopsis
- MRSA infective endocarditis (IE) has a high risk of complications and death, prompting a study to analyze patient data from Japan focusing on treatment and outcomes.
- The study involved 64 patients with MRSA-IE, revealing a high mortality rate of 28.1% at 30 days and 45.3% during hospitalization, with glycopeptides being the most commonly used initial treatment.
- While the choice of antibiotic therapy (glycopeptide, daptomycin, linezolid) did not significantly affect prognosis, further research is needed to identify the best first-line treatments for MRSA-IE.
Article Synopsis
- A nationwide surveillance study in Japan assessed the antimicrobial susceptibility of bacterial pathogens related to respiratory tract infections, collecting data from June 2019 to December 2020.
- The study analyzed 932 bacterial strains from 32 medical facilities, finding notable resistance rates, such as 35.3% for methicillin-resistant Staphylococcus aureus and 16.2% for β-lactamase-producing resistant Haemophilus influenzae.
- Results from this surveillance aim to inform treatment strategies for respiratory infections in Japan and promote the responsible use of antimicrobial drugs.
Community-acquired pneumonia (CAP) caused by in healthy adults can rapidly lead to severe outcomes. We treated a case of -induced CAP and concurrent severe coronavirus disease (COVID-19) in a healthy 39-year-old man without other serious risk factors for severe illness except smoking. Immediately after admission, the patient developed sepsis and received intensive broad-spectrum antibacterial therapy with meropenem and vancomycin, veno-arterial extracorporeal membrane oxygenation (VAECMO), and catecholamine supplementation.
View Article and Find Full Text PDF